Unmet need in CSU: Inadequately controlled patients

Inadequately controlled patients

How do you help your patients when…?

Up to 50% of CSU patients have an inadequate response to H1-antihistamines at licensed doses1,2

Beyond Xolair®, there are no other licensed treatment options for inadequately controlled CSU patients1

Until now, there has been no standard of care for these inadequately controlled CSU patients1

*Patient verbatim and profile comes from hypothetical patient for illustrative purpose only

Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

References: 1. Maurer M et al. Allergy 2011;66:317-330 2. Weller K, et al. J Eur Acad Dermatol Venereol 2013;27:43–50. 3. Maurer M, et al. N Engl J Med 2013;368:924-935. 4. Zuberbier T et al. Allergy 2014; 69:868-887

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma